Purchase Order 36C25025P0025
Award Date
10/1/24
Potential Completion Date
9/30/25
Potential Value
$213K
Federal Agency
Veterans Integrated Service Network 10
Awardee
Travere Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Foster City, CA 94404, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Travere Therapeutics, Inc. was awarded a $18,542.20 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to supply Thioproin pharmaceutical products. The delivery order was issued under Travere's Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB) for products to be delivered to the VA medical facility located in San Diego, California by June 2024. No set-aside designation was applied to this...
This is a federal contract award issued by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Travere Therapeutics, Inc. The contract is for the delivery of the pharmaceutical product Filspari, with a ceiling value of $11,280.64 and a completion date of December 18, 2024. The contract is a Delivery Order under Travere's Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB). Additionally, Travere holds two...
This federal contract award to Travere Therapeutics, Inc. is for the delivery of the drug Thiola Tiopronin. The contract, valued at $11,125.32, is a firm fixed price delivery order issued against Travere's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the U.S. Department of Veterans Affairs (VA). The award, which does not have a set-aside designation, has an ultimate completion date of August 26, 2024. Travere Therapeutics is a biopharmaceutical company specializing...
This is a firm fixed-price delivery order award to Travere Therapeutics, Inc., a biopharmaceutical company, by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21. The contract is for the supply of Travere's specialty pharmaceutical product Filspari 400mg, which is used to treat rare diseases affecting kidney and liver function. The award has a ceiling value of $7,354.26 and a period of performance through September 30, 2024. Travere Therapeutics holds a Federal Supply...
This is a federal contract award to Travere Therapeutics, Inc., a biopharmaceutical company, for the delivery of the pharmaceutical product Thiola 100 mg. The contract, valued at $11,125.32, was awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 (VISN 5) on August 26, 2024, with an ultimate completion date of August 27, 2024. The contract is a firm fixed price delivery order issued under Travere's Federal Supply Schedule (FSS) contract with the VA for...
Travere Therapeutics, Inc. was awarded a $11,280.58 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The delivery order was issued under Travere's Pharmaceuticals and Drugs General Services Administration Federal Supply Schedule contract to supply FILSPARI to VA medical facilities located in San Diego, California. No set-aside designation was applied to this award. Travere Therapeutics holds several...
Travere Therapeutics, Inc. has been awarded a $11,125.32 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to supply Thiola 100 MG pharmaceutical products. The delivery order was issued under Travere's Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB) with no set-aside applied, and performance will occur in San Diego, California by March 12, 2024. Travere specializes in developing therapies for...
The Department of Veterans Affairs has awarded a $236,500.00 firm fixed price contract to Travere Therapeutics, Inc. to provide the pharmaceutical product Chenodal (chenodiol) 250mg. The contract has a period of performance through March 23, 2024 and was not set aside for any specific business category. Travere Therapeutics is a biopharmaceutical company that specializes in rare disease therapies and has received multiple awards from the VA and other government agencies to supply specialty...
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order to Travere Therapeutics, Inc., a biopharmaceutical company, for the supply of Thiola (tiopronin), a drug used to treat cystinuria. The $19,987.10 award is part of Travere's Federal Supply Schedule (FSS) contract with the VA under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, valued at up to $14,970,593.10. The delivery order has an ultimate completion date of September 30, 2023. Travere Therapeutics also...
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Travere Therapeutics, Inc. for the delivery of the pharmaceutical product Chenodal. The firm fixed price purchase order, valued at $189,200.00, has a completion date of September 30, 2022. Travere Therapeutics is a biopharmaceutical company that specializes in rare disease therapies and has received numerous federal contract awards from the VA and other agencies to supply...